Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis

Recruiting now

Conditions studied: Intra-Abdominal Infection, Candida, Abdominal Surgery Patients, Critically Ill Intensive Care Unit Patients

In brief

ntra-abdominal candidiasis is a serious infection common in critically ill patients, often leading to high mortality if not treated quickly. Standard antifungal treatments may be less effective due to growing resistance and poor drug penetration into the abdominal cavity. In critically ill patients, drug levels can vary widely due to factors like surgery, inflammation, fluid resuscitation, or extracorporeal support, increasing the risk of underdosing. Rezafungin is a new antifungal agent with a long half-life and broad activity against Candida species, offering potential advantages in this setting. However, there is currently no data on its concentration or effectiveness in the peritoneal fluid of patients with intra-abdominal sepsis. Its long half-life, coupled with repeated pharmacokinetic variations in critical care settings and the risk of insufficient concentrations, may hinder its use in this population.

Key facts

Study ID

NCT07093203

Run by

Central Hospital, Nancy, France

People needed

20

Starts

2025-11-14

Expected to finish

2026-09-01

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age > 18 years
• with a suspected intra-abdominal candidiasis requiring abdominal surgery
• and receiving the administration of rezafungin as first-line empirical antifungal treatment just before or within 1 hour the abdominal surgery
• and having abdominal drain for at least 2 days after the surgery

You may not qualify if…

• death expected within 24h
• decline to participate

Where it is running

• CHRU de Nancy — Vandœuvre-lès-Nancy, Lorraine, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.